Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole augmentation in treatment refractory depression
NCT00608543Phase 4Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aripiprazole in major depressive disorder (MDD), sponsored by UT Southwestern Medical Center. Primary endpoints: Stockings of Cambridge Mean Initial Thinking Time for 3-move Problems at 6 weeks, Stockings of Cambridge Mean Initial Thinking Time for 5-move Problems at 6 weeks and 2 more. Started Oct 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00608543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00608543.